Since many studies have been attempting to find currently available or novel anti-tumor agents which are selectively effective for tumors with dysfunctional RB1, the CCND1/CDKN2A ratio expression assay might contribute to patient stratification as a highly accurate, quantitative, and less invasive biomarker. This evidence concerns the gene CDKN2A and neoplasm.